N30 Pharma is a privately held, clinical-stage, biopharmaceutical company headquartered in Boulder, Colorado. It is the first company to discover and develop small molecules targeting GSNOR. N30 Pharma is dedicated to making a difference in the lives of patients with cystic fibrosis and their families.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 11/21/14 | $30,000,000 | Mezzanine |
Deerfield Management Company, L.P. Jennison Associates RA Capital Rock Springs Capital Sabby Capital Wellington Management Company | undisclosed |
